SI-BONE, Inc. (SIBN)
- Previous Close
16.06 - Open
16.08 - Bid 16.29 x 100
- Ask 16.35 x 200
- Day's Range
15.89 - 16.71 - 52 Week Range
11.76 - 23.25 - Volume
150,479 - Avg. Volume
357,563 - Market Cap (intraday)
680.031M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-1.00 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.56
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
si-bone.comRecent News: SIBN
View MorePerformance Overview: SIBN
Trailing total returns as of 8/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SIBN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SIBN
View MoreValuation Measures
Market Cap
669.61M
Enterprise Value
556.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.35
Price/Book (mrq)
4.06
Enterprise Value/Revenue
3.69
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.10%
Return on Assets (ttm)
-12.51%
Return on Equity (ttm)
-23.88%
Revenue (ttm)
150.71M
Net Income Avi to Common (ttm)
-40.85M
Diluted EPS (ttm)
-1.00
Balance Sheet and Cash Flow
Total Cash (mrq)
151.53M
Total Debt/Equity (mrq)
23.32%
Levered Free Cash Flow (ttm)
-11.71M